Astellas Pharma Inc. (OTCMKT: ALPMY, ALPMF, TYO: 4503) was founded in 1923 and is headquartered in Tokyo, Japan. It has 17,217 full-time employees. It is a leading pharmaceutical company in Japan. It was established on April 1, 2005. Japan was formed by the merger of Yamanouchi Pharmaceutical Co., Ltd. (Yamanouchi Pharmaceutical Co., Ltd.) and Fujisawa Pharmaceutical Co., Ltd. of Japan.
Astellas Pharma (ALPMY):
Astellas is derived from the Latin “stella”, the Greek “aster”, and the English “stellar”. It means “star” and is expressed as “aspired stars”, “advanced stars”, and Japanese The pronunciation of “light up the sky” is similar. This name implies that Astellas, as a global pharmaceutical company originating from Japan, is committed to the research and development of advanced high-quality pharmaceutical products, to send hope and future to people who desire health in the world, and to continue to move forward.
Astellas Pharmaceutical Group is a pharmaceutical company dedicated to providing innovative and reliable medicines and improving human health worldwide. The group is determined to be at the forefront of the ever-changing medical industry and transform scientific progress into patient value.
In the 2014 fiscal year (April 2014 to March 2015), Astellas Pharmaceuticals Group’s global sales reached 10.394 billion US dollars, and the pharmaceutical research and development investment was 1.722 billion US dollars, accounting for 16.6% of global sales revenue. Currently, global employees More than 17,000 people.
Astellas plans to invest sufficient resources to ensure that we can continue to produce innovative drugs by keeping the proportion of R&D investment not less than 17% of net sales. Astellas has focused on five key R&D areas of urinary, transplantation immune/infectious diseases, oncology, neuroscience and diabetic complications/nephropathy, and expanded two new therapeutic areas for muscle diseases and ophthalmology.
In addition, Astellas foresaw the environmental changes faced by the innovative drug market, and continued to actively explore new business opportunities in unexplored new areas.
Astellas Pharma (ALPMY) product:
- Prograf (tacrolimus)-used to prevent organ rejection after transplantation
- Protopic (tacrolimus ointment, tacrolimus ointment)-for atopic dermatitis (eczema)
- Amevive (alefacept)-for plaque psoriasis (Plaque psoriasis)
- VESIcare (solifenacin succinate, solfinacin succinate)-for overactive bladder (OAB), joint marketing with GlaxoSmithKline
- Myrbetriq (mirabegron)-for overactive bladder (OAB), only sold in the US; outside the US, Pfizer is responsible for sales
- Flomax (tamsulosin hydrochloride, tamsulosin hydrochloride)-for benign prostatic hyperplasia (BPH)
- Adenocard (adenosine injection)-pharmacological stress agent for myocardial perfusion scan
- Adenoscan (adenosine injection)-pharmacological stress agent for myocardial perfusion scan
- Lexiscan (regadenoson injection)-pharmacological stress agent for myocardial perfusion scan
- Vaprisol (conivaptan)-for hyponatremia (Hyponatremia)
- AmBisome (amphotericin B)-antifungal drug
- Cresemba (isavuconazole)-antifungal
- Mycamine (micafungin sodium)-antifungal drug
- Symoron (methadone HCL)-Get rid of narcotic abuse
- Tarceva (erlotinib)-for non-small cell lung cancer and pancreatic cancer
- Xtandi (enzalutamide)-for prostate cancer
Astellas Pharma (ALPMY) History:
1. History of Yamanouchi Pharmaceutical
- In 1923, Kenji Yamauchi established the Yamauchi Pharmaceutical Chamber of Commerce in Osaka;
- In 1940, the name was changed to Yamanouchi Pharmaceutical;
- In 1942, the headquarters was moved to Tokyo;
- In 1970, the antibiotic product “Josamycin” was launched;
- In 1981, developed the antihypertensive drug “Perdipine”;
- In 1985, developed and marketed Gaoshuda, an H2 receptor antagonist that inhibits gastric acid secretion, and is currently sold in more than 100 countries around the world;
- In 1986, the establishment of Irish Mountain in Europe, took the first step in overseas operations and production;
- In 1990, acquired Royal Gist Brocades Pharmaceutical Division (Netherlands);
- In 1993, “Harle” was developed and marketed, and it is currently sold in more than 90 countries around the world;
- Founded in Shenyang Mountain in China in 1994;
- In 2000, the drug “Lipitor” was launched for the treatment of hyperlipidemia;
- In 2001, Yamanouchi America Company was established and entered the American market;
- In 2004, “Weixikang” was launched in Europe to treat overactive bladder, and in the United States in 2005.
2. History of Fujisawa Pharmaceutical
- In 1894, Fujisawa Yoshiji established the Fujisawa Store in Osaka;
- In 1897, developed and marketed the household insecticide “Fujisawa Camphor”;
- In 1943, the company changed its name to Fujisawa Pharmaceutical Industry;
- In 1971, developed and marketed the antibiotic “Cefazolin” for injection;
- In 1977, Fujisawa Pharmaceutical Company was established in the United States;
- In 1979, the London office was opened;
- In 1991, Fujisawa Pharmaceuticals Germany branch was established;
- In 1993, developed and marketed the immunosuppressant “Pule Kefu”, which is currently sold in more than 80 countries around the world;
- In 1998, the U.S. branch was reorganized and Fujisawa Health Care was established;
- In 1999, “Proterbi”, which was launched to treat atopic dermatitis, is currently sold in more than 60 countries around the world.
3. History of Astellas Pharma Inc.
- In 2004, the over-the-counter businesses of the two companies were integrated to form Zepharma Inc.;
- On April 1, 2005, Astellas Pharmaceutical Group was established;
- In May 2005, Astellas’ antifungal drug “Mi Kaimin” was launched;
- In 2006, Astellas Pharma completed the merger of branches in most countries and regions around the world;
- In April 2006, Astellas Pharmaceuticals launched the drug “Vaprisol” for the treatment of hyponatremia in the United States;
- In April 2006, Zepharma, a subsidiary of Astellas Pharma in the non-prescription drug field, was transferred;
- In June 2006, Astellas Pharmaceuticals launched “Weixikang” for the treatment of overactive bladder in Japan;
- In December 2006, Astellas Pharma released the Astellas Vision 2015 (VISION 2015), which determined a competitive business model—that is, to become a “global professional therapy leader” in five core key therapeutic areas;
- In April 2007, Astellas Pharmaceuticals (China) Co., Ltd. completed the merger;
- In June 2007, Astellas Pharma launched a new generation of immunosuppressant “Xinpu Le Kefu” in Europe;
- In January 2008, Astellas Pharmaceuticals acquired Agensys from the United States, aiming to strengthen antibody research capabilities and further improve basic drug research technology;
- In April 2008, Astellas Pharma’s global clinical development headquarters (Astellas Pharmaceuticals Global Development Company) was established and started operations in the United States, aiming to accelerate product development and listing, and enhance global competitiveness;
- In October 2008, the Tsukuba Research and Development Center of Astellas Pharmaceuticals was completed, 2.6 times the original scale, and is Japan’s most advanced innovative drug research center;
- In May 2010, Astellas Pharma merged with OSI pharmaceutical companies focusing on the research and development of molecular targeted therapies to strengthen the products and business platforms in the oncology field;
- On June 9, 2010, Astellas Pharmaceuticals acquired OSI Pharmaceuticals for US$4 billion;
- In May 2016, Astellas Pharma acquired Ocata Therapeutics ;
- In 2016, Astellas Pharmaceuticals acquired Ganymed Pharmaceuticals;
- In April 2017, Astellas Pharmaceuticals announced that it would acquire Ogeda, a Belgian drug development company, for 800 million euros, and use the latter’s GPCR targeted drug candidate, fezolinetant, to enhance its late-stage pipeline. ).